A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

NCTID	NCT06539208 (View at clinicaltrials.gov)
Description	This study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YOLT-201 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis with cardiomyopathy (ATTRv-CM). (Show More)
Development Status	Active
Indication	Transthyretin Amyloidosis Polyneuropathy, Transthyrexin Amyloidosis Cardiomyopathy
Disease Ontology Term	DOID:0050638
Compound Name	YOLT-201
Sponsor	YolTech Therapeutics Co., Ltd
Funder Type	Industry
Recruitment Status	Recruiting
Enrollment Count	31
Results Posted	Not Available

No.of Trial Sites	3
Locations	China

Has US IND	False
FDA Designations
Recent Updates	Dose escalation completed December 2024